PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19998502-11	2009	LDH release from HepG2 cells was analyzed at 24, 48, 72 and 96 h after infection with LV-NT4(Si)-p53(N15)-Ant and LV-EGFP, which showed that LDH release was significantly higher in LV-NT4(Si)-p53(N15)-Ant treatment group (682 IU/L) than in control group (45 IU/L, P < 0.01).	Leucovorin	86-88	tumor protein p53	Homo sapiens	97-100	
15342418-1	2004	We have demonstrated previously that interferon (IFN)-gamma sensitizes human colon carcinoma cell lines to the cytotoxic effects of 5-fluorouracil combined with leucovorin and to the thymidylate synthase inhibitor, ZD9331, dependent on thymineless stress-induced DNA damage, independent of p53.	Leucovorin	161-171	tumor protein p53	Homo sapiens	290-293	
16528528-10	2006	FDXR gene expression, which is regulated at least in part by p53, is associated with both response and survival when metastatic colorectal cancer is treated with 5-FU plus LV.	Leucovorin	172-174	tumor protein p53	Homo sapiens	61-64	
15611505-0	2004	Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.	Leucovorin	67-77	tumor protein p53	Homo sapiens	14-18	
12171874-1	2002	Potentiation of 5-fluorouracil/leucovorin (FUra/LV) cytotoxicity by IFN-gamma in colon carcinoma cells is dependent on FUra-induced DNA damage, the Fas death receptor, and independent of p53 and RNA-mediated FUra toxicity, which occurs in normal gastrointestinal tissues.	Leucovorin	31-41	tumor protein p53	Homo sapiens	187-190	
14695155-2	2003	Importantly, the cytotoxic effects of thymidine deprivation induced by 5-fluorouracil (FUra) combined with leucovorin (LV) was enhanced by IFN-gamma, and the synergism was shown to be dependent on Fas, FUra-induced DNA damage, and independent of p53.	Leucovorin	107-117	tumor protein p53	Homo sapiens	246-249	
14695155-2	2003	Importantly, the cytotoxic effects of thymidine deprivation induced by 5-fluorouracil (FUra) combined with leucovorin (LV) was enhanced by IFN-gamma, and the synergism was shown to be dependent on Fas, FUra-induced DNA damage, and independent of p53.	Leucovorin	119-121	tumor protein p53	Homo sapiens	246-249	
12171874-1	2002	Potentiation of 5-fluorouracil/leucovorin (FUra/LV) cytotoxicity by IFN-gamma in colon carcinoma cells is dependent on FUra-induced DNA damage, the Fas death receptor, and independent of p53 and RNA-mediated FUra toxicity, which occurs in normal gastrointestinal tissues.	Leucovorin	48-50	tumor protein p53	Homo sapiens	187-190	
11038045-1	2000	BACKGROUND: We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU) leucovorin (LV) combination.	Leucovorin	217-227	tumor protein p53	Homo sapiens	58-61	
11802206-0	2002	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.	Leucovorin	83-93	tumor protein p53	Homo sapiens	0-3	
11038045-1	2000	BACKGROUND: We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU) leucovorin (LV) combination.	Leucovorin	229-231	tumor protein p53	Homo sapiens	58-61	
21541641-4	1996	Increased p53 protein levels have previously been shown to correlate with disease progression in a series of colorectal carcinoma patients treated with 5-FU/folinic acid biomodulated chemotherapy.	Leucovorin	157-169	tumor protein p53	Homo sapiens	10-13	
32731241-5	2020	Intestinal-type adenocarcinoma carrying a functional p53 protein may be treated with preoperative cisplatin, 5-fluorouracil, and leucovorin.	Leucovorin	129-139	tumor protein p53	Homo sapiens	53-56	
31897925-10	2020	Neoadjuvant chemotherapy with cisplatin, 5-fluorouracil and leucovorin may offer high response rates and long-term control in a subgroup of patients affected by intestinal-type adenocarcinoma, and in particular in those whose tumors harbor a functional p53 protein.	Leucovorin	60-70	tumor protein p53	Homo sapiens	253-256